Medicare coverage and Lilly’s new oral weight-loss drug could unlock another powerful growth phase as the company strengthens its lead over Novo Nordisk.
The pharmaceutical giant continues unlocking powerful growth opportunities across multiple markets.
Lilly's expanding pipeline may strengthen its position in a rapidly growing market.
The next phase of GLP-1 growth could extend far beyond what Zepbound already achieved.
Pricing pressure and demand uncertainty are now becoming harder for investors to ignore.
Why today’s headline partnership matters more than it first appears.
What Novo Nordisk’s pill means for long-term investors.
